



NEWS RELEASE

CareDx Congratulates Board Member Dr. Grace Colón for Being Named Healthcare Innovator on Top 50 Most Powerful Latinas List

2022-09-26

The Association of Latino Professionals For America Recognizes the Most Powerful Latinas in Business, Technology, Healthcare, and Non-Profit Sectors

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Dr. Grace Colón, a member of its Board of Directors, has been named on the 2022 Most Powerful Latinas list by The Association of Latino Professionals For America (ALPFA).

“We congratulate Dr. Colón for being named a healthcare innovator by ALPFA and for her significant contribution in driving innovation to improve patient care,” said Michael D. Goldberg, Chairman of the Board, CareDx. “As Chair of CareDx’s Science and Technology Committee she has played an invaluable role in helping shape the company’s innovation agenda focused on improving the transplant patient journey.”

Dr. Colón joined the CareDx Board of Directors in July 2019. She has served as President, Chief Executive Officer and Director of InCarda Therapeutics, Inc., a clinical stage company developing therapeutics for cardiovascular conditions, since 2013. In addition to her role at InCarda, she is also Executive Chairman (formerly Chief Executive Officer) of ProterixBio and sits on the boards of the MIT Corporation and the Biotechnology Innovation Organization. For more details on Dr. Colón’s bio go [here](#).

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CareDx, Inc.

Media Relations

Anna Czene

818-731-2203

[aczene@caredx.com](mailto:aczene@ caredx.com)

Investor Relations

Ian Cooney

(415) 722-4563

investor@CareDx.com

Source: CareDx, Inc.